Ocuphire Pharma Results

APX3330 VEGF Effects in Normal Cells APX3330 Restores Normal Levels Unlike Biologic Anti-VEGFs that Reduce VEGF Below Normal Normal Conditions: Physiological level of VEGF activity Abnormal Conditions (e.g., hypoxic): Increased level of VEGF activity Biologic anti-VEGF agents inactivate VEGF directly and reduce VEGF levels below normal levels Biologic Anti-VEGF Treatment APX3330 Anti-Ref-1 Treatment Inhibition of Ref-1 by APX3330 returns VEGF levels to normal levels APX3330 prevents VEGF overproduction in ARPE-19 cells VEGF Concentrations (% of Control) Ocuphire Kamba 2007; Girardi 2010; Li 2014; APX3330 Investigator Brochure PHARMA 500 450 400 350 300 250 200 150 100 50 0 oxLDL APX3330 ARPE-19 cell line + * p<0.05 + 150µg/mL + 30μM VEGF is a growth factor that is necessary for normal function of multiple cell types including vascular endothelium and neurons → By returning VEGF levels to normal, APX3330 can reduce neovascularization, vascular leakage and the inflammatory response without adverse systemic effects The safety profile of APX3330 to date in over 300 subjects has not shown any of the adverse effects that has been seen with systemic administration of anti-VEGF biologics such as cardiovascular pathology, hypertension, arteriothrombotic events, or renal dysfunction 34

View entire presentation